Navigating Presbyopia Conversations with Patients in Practice
Optometry 360
Home > GLP-1 receptor agonist use tied to higher NAION risk

GLP-1 receptor agonist use tied to higher NAION risk

Ophthalmology 360

Key Takeaways

  1. GLP-1 RA use was associated with higher odds of NAION, although the absolute risk was low.
  2. No association was found between GLP-1 RAs and overall ocular events.

Use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) was associated with a modestly increased risk of nonarteritic ischemic optic neuropathy (NAION), according to data from a meta-analysis of more than 1.5 million patients presented at the 59th Annual Scientific Meeting of The Retina Society.

The analysis included 15 longitudinal studies, 8 of which were randomized trials.

Overall, GLP-1 RA use was associated with a 70% higher odds of NAION. The association was also seen in nonrandomized studies, while randomized studies showed a higher estimated risk that did not reach statistical significance.

The presenters highlighted the need for long-term postmarketing safety studies.

Reference

Maia M, et al. Association Between GLP-1 Receptor Agonists and Ischemic Optic Neuropathy: A Meta-Analysis.Presented at: 59th Annual Scientific Meeting of The Retina Society; September 23-26, 2026; Los Angeles, CA.

Related Content